Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to
reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced …

Abstract Sickle Cell Disease (SCD) is one of the most inherited hematologic diseases
affecting humans. Clinically, there is a progressive multiorgan failure and increased mortality …

Sickle-cell disease (SCD) is characterized by frequent and painful vaso-occlusive crises
(VOCs). Various treatments have been evaluated over the years. However, a clear overview …

Abstract Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the
frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated …

Painful vaso-occlusive crisis (VOC) remains the most common reason for presenting to the
Emergency Department and hospitalization in patients with sickle cell disease (SCD) …

Early diagnosis, treatment, and prevention of a vaso‐occlusive crisis (VOC) are critical to the
management of patients with sickle cell disease. It is essential to differentiate between VOC …

Objectives This study evaluated the prevalence rate of vaso-occlusive crisis (VOC)
episodes, rates of uncomplicated and complicated VOC episodes, and the primary reasons …

2. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus
CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell …

Background: Sickle cell disease (SCD) is a genetic disorder in which deoxygenation
produces polymerization of mutated hemoglobin S (HbS) and triggers the downstream …

Family physicians are the primary and sometimes only health care resource for families
affected by sickle cell disease. Recently published guidelines provide important …